How coffee protects your liver
March 24, 2016
Psoriasis raises type 2 diabetes risk, severity influenced by intensity of the skin disorder
March 24, 2016
Show all

Protein Determines Rheumatoid Arthritis Disease Activity

Experts have learned about a new protein that affects the damage done in cases of severe rheumatoid arthritis.

A new protein that regulates the damage done in cases of severe rheumatoid arthritis (RA) has been identified, according to a study published in the Proceedings of the National Academy of Sciences.

Researchers from the University College Dublin analyzed DNA and biopsy samples from the joints of more than 1,000 RA patients in the United Kingdom and Ireland. The researchers noted that even though there is no current cure for RA, the current drugs on the market can treat the disease and prevent deformed joints. They added that self-management of the condition and patient exercise can reduce pain and the resulting disability, as well.

The researchers said the protein, called C5orf30, was found to control the severity of tissue damage caused by RA.

“Our findings provide a genetic marker that could be used to identify those RA patients who require more aggressive treatments or personalized medicine,” researcher leader Professor Gerry Wilson explained in a press release. “They also point to the possibility that increasing the levels of C5orf30 in the joints might be a novel method of reducing tissue damage caused by RA.”

The researchers believe that the patients who are more likely to suffer the most severe RA treatment should be able to be fast tracked to the more aggressive treatments right away. In the future, they said, they will be able to probe into the protein and determine its significance to human health and disease.
Read Full Article: Protein Determines Rheumatoid Arthritis Disease Activity

 

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.